Cenegermin

Phase 3Protein / enzyme

Cenegermin is one of 7 small molecule programs targeting Persistent Corneal Epithelial Defect. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Persistent Corneal Epithelial DefectRecruiting

Anterior Ischemic Optic NeuropathyRecruiting

Persistent Corneal Epithelial DefectPhase 3

Recruiting

Anterior Ischemic Optic NeuropathyPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Anterior Ischemic Optic Neuropathy

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Approved

—2

Ampyra

MMerz North America, Inc.

Approved

1 3

Kenalog

BBausch Health Americas, Inc.

Kenalog

Caverject

VViatris Specialty LLC

Approved

—6

Cenegermin

DDompé Farmaceutici S.p.A

Phase 3

1 7

Bayer Aspirin

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Anterior Ischemic Optic Neuropathy

NCT07453888

Q4 2027

Phase 3Recruiting

Persistent Corneal Epithelial Defect

NCT07519902

Clinical

Trials by Indication[1]

Eye Disease1 trial

Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease

Completed·DDompé Farmaceutici S.p.A·Phase 3·NCT05136170·85 enrolled

Treatment1 trial

Corneal Nerves After Treatment With Cenegermin

Completed·UUniversity of California, Los Angeles··NCT04627571·8 enrolled

Keratitis1 trial

DOMPE -MT Neurotrophic Keratitis

Active, not recruiting·TToyos Clinic·Phase 4·NCT06947850·10 enrolled

Anterior Ischemic Optic Neuropathy1 trial

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Recruiting·DDompé Farmaceutici S.p.A·Phase 3·NCT07453888·272 enrolled

Persistent Corneal Epithelial Defect1 trial

Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)

Recruiting·DDompé Farmaceutici S.p.A·Phase 3·NCT07519902·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Cenegermin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenegermin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenegermin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dompé Farmaceutici S.p.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: DDompé Farmaceutici S.p.A

Cenegermin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Eye Disease1 trial

Treatment1 trial

Keratitis1 trial

Anterior Ischemic Optic Neuropathy1 trial

Persistent Corneal Epithelial Defect1 trial

References

Drug Info

Quick Facts

Related News